Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Shanghai Zhimeng Starts US Phase I Trial of Novel HBV Treatment

publication date: Mar 5, 2020

Shanghai Zhimeng Biopharma started first-in-human dosing of its novel, investigational HBV capsid formation inhibitor in a US Phase I trial. Zhimeng is developing ZM-H1505R for chronic HBV infection. Unlike core protein allosteric modulators, ZM-H1505R is a novel pyrazole molecule with a new binding site in the HBV core protein that inhibits HBV replication. The company expects the candidate will be a cure for HBV, not a treatment. Immediately following this trial, Zhimeng plans to start a China clinical study of ZM-H1505R in HBV-infected patients. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital